Compare Credo Technology Group Holding Ltd (CRDO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Summit Therapeutics Inc — how do they compare? Credo Technology Group Holding Ltd trades at $214.72 (market cap $39.82B), while Summit Therapeutics Inc trades at $17.44 (market cap $13.71B). The key difference: Credo Technology Group Holding Ltd is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Summit Therapeutics Inc for 16 Days on average.
| CRDO | SMMT | |
|---|---|---|
Market Cap | $39.82B | $13.71B |
Volume | 9,451,558 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $302.52 | $26.38 |
52-Week Low | $87.81 | $12.43 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $39.08B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $213.95, down 2.75% today but maintains strong technical support near $214. The company demonstrates exceptional fundamental performance with 114.7% YoY revenue growth and 33.83% net margins. Recent earnings beats and bullish analyst consensus at 87.5% buy ratings support the positive outlook. Technical indicators show bullish moving averages while oscillators remain neutral, with key support at $204 and resistance at $222.
CRDO presents compelling growth potential driven by AI infrastructure demand, with consensus price target of $267.33 offering 25% upside. Risks include premium valuation (P/E 74.6) and customer concentration, but strong cash flow generation and expanding optical business provide fundamental support. The stock's recent pullback may offer entry opportunity for growth investors.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
